News|Articles|November 18, 2026 (Updated: November 18, 2026)

Semaglutide Reduces BMI by 13.5% in Children Aged 6-11 in Step Young Trial

Fact checked by: Abigail Brooks, MA

ObesityWeek 2026: Once-weekly semaglutide reduced BMI by 13.5% vs a 2.7% gain with placebo at 68 weeks in children 6 to <12 years with obesity.

Once-weekly semaglutide (Wegovy®; Novo Nordisk) significantly reduced body mass index (BMI) and improved obesity classification among children aged 6 to younger than 12 years with obesity, according to findings from the phase 3 STEP Young clinical trial published November 16, 2026, in The New England Journal of Medicine and presented at ObesityWeek 2026 in Washington, DC.¹

At week 68, children receiving semaglutide experienced a mean BMI reduction of 13.5%, compared with a 2.7% increase among those receiving placebo, representing a statistically significant between-group difference of −16.2 percentage points (95% CI, −19.4 to −12.9; P < .001). Additionally, 79% of children receiving semaglutide moved to a lower BMI category, compared with 23% receiving placebo (odds ratio [OR], 7.8; 95% CI, 3.5-17.6; P < .001).¹

The findings provide new evidence supporting the potential use of glucagon-like peptide-1 (GLP-1) receptor agonist therapy in younger children with obesity, a population with limited approved pharmacologic treatment options.

Investigators led by Ania M. Jastreboff, MD, PhD, professor of medicine and pediatrics at Yale School of Medicine and director of the Yale Obesity Research Center, evaluated the efficacy and safety of once-weekly subcutaneous semaglutide in children with obesity.

"Severe obesity can profoundly affect a child’s physical health, emotional well-being, and daily life. This chronic disease also increases the risk of many obesity-related complications that can emerge early and persist into adulthood," Jastreboff said in a November 16 press release from Novo Nordisk.²

"Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child’s trajectory back towards one of improving weight related health," she continued.

How Was Semaglutide Evaluated in Children Younger Than 12 Years?

STEP Young (NCT05726227) was a phase 3, randomized, double-blind, placebo-controlled trial evaluating once-weekly subcutaneous semaglutide in children aged 6 to younger than 12 years with obesity.¹

The study included 167 children randomized in a 2:1 ratio to receive semaglutide (n=112) or placebo (n=55) for 104 weeks, followed by a 7-week treatment-free follow-up period.

Semaglutide was administered at a maximum dose of 1.7 mg or 2.4 mg based on baseline body weight or the maximum tolerated dose. Children weighing 45 to 60 kg at baseline received a maximum dose of 1.7 mg, while those weighing more than 60 kg could receive 2.4 mg.²

KEY TAKEAWAYS

  • STEP Young Trial demonstrated semaglutide reduced BMI by 13.5% in children aged 6-11 with obesity at week 68, versus a 2.7% increase with placebo.
  • In the STEP Young Trial, 79% of semaglutide-treated children improved to a lower BMI category compared with 23% receiving placebo.
  • STEP Young Trial data showed 38.4% of semaglutide recipients no longer met obesity classification criteria, versus 2.1% in the placebo group.
  • Semaglutide-associated BMI reductions in STEP Young Trial persisted through week 104, though magnitude was smaller than the week 68 primary endpoint.

Both treatment groups received lifestyle modification counseling, including guidance on a reduced-calorie diet and increased physical activity.

More than 85% of participants had class II or III severe obesity at baseline, underscoring the substantial disease burden among children enrolled in the trial.

The primary endpoint was percentage change in BMI from baseline to week 68, while the confirmatory secondary endpoint was improvement in BMI category at the same time point. Additional analyses evaluated outcomes through 104 weeks and the safety and tolerability of treatment.

How Much Did Semaglutide Reduce BMI at 68 Weeks?

At week 68, semaglutide was associated with significantly greater BMI reductions than placebo in the primary treatment-regimen analysis, which evaluated treatment effects regardless of whether participants remained on the assigned medication.

Mean BMI decreased by 13.5% among children receiving semaglutide, compared with an increase of 2.7% among placebo recipients, corresponding to a between-group difference of −16.2 percentage points (95% CI, −19.4 to −12.9; P < .001).¹

In a separate efficacy analysis estimating outcomes if all participants had adhered to treatment without using additional weight-management interventions, mean BMI decreased by 17.4% with semaglutide compared with a 2.2% increase with placebo. The estimated between-group difference was −19.7 percentage points (95% CI, −23.1 to −16.2; P < .001).²

The trial also demonstrated substantial improvements in BMI classification.

At week 68, 78.8% of children receiving semaglutide improved by at least 1 BMI category compared with 23.4% receiving placebo (OR, 7.8; 95% CI, 3.5-17.6; P < .001).

Additionally, 38.4% of children receiving semaglutide were no longer classified as having obesity, defined as a BMI below the 95th percentile for age and sex, compared with 2.1% receiving placebo.


Treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child’s trajectory back towards one of improving weight related health.

In the efficacy analysis, 83.0% of semaglutide recipients improved their BMI category, while 40.4% had a BMI below the obesity threshold. Corresponding proportions in the placebo group were 23.5% and 0%, respectively.²

Nearly 79% of children receiving semaglutide in the efficacy analysis achieved a BMI reduction of at least 10%, compared with no placebo recipients. In the observed treatment-regimen analysis, the corresponding proportions were 74.7% and 4.3%.

Were BMI Improvements Maintained Through 104 Weeks?

Semaglutide-associated BMI reductions persisted through 104 weeks, although the magnitude of reduction was smaller than at the primary 68-week assessment.

At week 104, mean BMI had decreased by 9.4% from baseline among children receiving semaglutide, compared with an 8.4% increase among placebo recipients, representing a between-group difference of −17.8 percentage points (95% CI, −22.2 to −13.3).¹

In the efficacy analysis, mean BMI decreased by 14.0% with semaglutide compared with a 5.7% increase with placebo.

At week 104, 77.1% of children receiving semaglutide had improved their BMI category compared with 24.4% receiving placebo. Approximately one-third (33.3%) of semaglutide recipients were no longer classified as having obesity, compared with 2.4% of placebo recipients.²

However, Novo Nordisk noted that week 104 secondary endpoint analyses were not adjusted for multiple comparisons and should be interpreted as supportive rather than definitive evidence of treatment effects.

What Were the Safety Findings in STEP Young?

The overall safety profile of semaglutide was consistent with previous clinical trials involving adolescents and adults, according to the investigators.

Adverse events occurred in 96% of children receiving semaglutide and 93% receiving placebo. Gastrointestinal adverse events were the most frequently reported and occurred more often with semaglutide.¹

Gastrointestinal adverse events led to treatment discontinuation in 1 child receiving semaglutide.

Novo Nordisk reported that no unexpected safety signals were identified, including no identified safety concerns related to growth or pubertal development during the trial.²

However, the long-term effects of semaglutide treatment initiated in childhood, particularly regarding growth, development, and sustained weight management, require continued investigation.

Semaglutide also carries a boxed warning concerning thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

What Do the Findings Mean for Pediatric Obesity Management in Primary Care?

The STEP Young findings may be particularly relevant for primary care physicians and pediatricians managing children with severe obesity who have limited options for pharmacologic treatment.

Childhood obesity is associated with increased risks of type 2 diabetes, dyslipidemia, hypertension, obstructive sleep apnea, and other cardiometabolic complications that can persist into adulthood.

The trial provides evidence that semaglutide, when combined with lifestyle modification, can produce substantial BMI reductions and improve obesity classification in children younger than 12 years.

However, the results do not establish the long-term effects of treatment on cardiovascular outcomes, diabetes incidence, or other obesity-related complications.

The relatively small sample size and limited follow-up beyond treatment discontinuation also leave questions regarding long-term safety, treatment duration, and weight regain after stopping therapy.

For primary care physicians, the findings reinforce the importance of early identification and comprehensive management of childhood obesity, including family-centered behavioral interventions, nutritional counseling, physical activity support, and assessment for obesity-related complications.

Semaglutide is currently FDA approved for chronic weight management in adolescents aged 12 years and older and adults, but is not approved in the US for children younger than 12 years. Its use in this younger population remains investigational.

The investigators concluded that once-weekly semaglutide significantly reduced BMI and improved obesity classification compared with placebo among children aged 6 to younger than 12 years, supporting continued investigation of GLP-1 receptor agonist treatment for severe childhood obesity.


References

  1. Jastreboff AM, Harder-Lauridsen NM, Van Name M, et al. Semaglutide for the treatment of obesity in children 6 to younger than 12 years of age. N Engl J Med. Published online November 16, 2026. doi:10.1056/NEJMoa2604058.
  2. Novo Nordisk. Wegovy resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine. News release. November 16, 2026.
  3. ClinicalTrials.gov. Semaglutide in children with obesity (STEP Young). NCT05726227.

Related to this article